Cytosorbents Corp
NASDAQ:CTSO
Cytosorbents Corp
Research & Development
Cytosorbents Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cytosorbents Corp
NASDAQ:CTSO
|
Research & Development
-$5.1m
|
CAGR 3-Years
34%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-4%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Research & Development
-$1.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Research & Development
-$2.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-9%
|
|
|
Stryker Corp
NYSE:SYK
|
Research & Development
-$1.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Research & Development
-$2.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Research & Development
-$1.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-21%
|
|
Cytosorbents Corp
Glance View
CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Monmouth Junction, New Jersey and currently employs 221 full-time employees. The company went IPO on 2005-06-17. The firm is engaged in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via its polymer adsorption technology. The firm's lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy and pancreatitis. Its other products include animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. The firm's product candidates under development includes CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent and porous polymer beads.
See Also
What is Cytosorbents Corp's Research & Development?
Research & Development
-5.1m
USD
Based on the financial report for Sep 30, 2025, Cytosorbents Corp's Research & Development amounts to -5.1m USD.
What is Cytosorbents Corp's Research & Development growth rate?
Research & Development CAGR 10Y
-4%
Over the last year, the Research & Development growth was 47%. The average annual Research & Development growth rates for Cytosorbents Corp have been 34% over the past three years , 12% over the past five years , and -4% over the past ten years .
